Sirolimus Is Associated With Reduced Islet Engraftment and Impaired β-Cell Function

Successful islet transplantation depends on the infusion of sufficiently large quantities of islets, but only a fraction of transplanted islets can survive and become engrafted, and yet the underlying mechanism remains unclear. In this study, we examined the effect of sirolimus, a key component of the immunosuppressive regimen in clinical islet transplantation, on islet engraftment and function. To distinguish the effect of sirolimus on immune rejection from its effect on islet engraftment, we used a syngeneic model. Diabetic mice were transplanted with 250 islets under the renal capsule, followed by treatment with sirolimus or vehicle for 14 days. Thirty days posttransplantation, islet grafts were retrieved for the determination of insulin content and vascular density. Compared with mock-treated controls, diabetic recipient mice receiving sirolimus exhibited impaired blood glucose profiles and reduced glucose-stimulated insulin secretion, correlating with reduced intragraft insulin content and decreased vascular density. Islets exposed to sirolimus for 24 h in culture displayed significantly diminished glucose-stimulated insulin release, coinciding with decreased pancreas duodenum homeobox-1 and GLUT2 expression in cultured islets. Furthermore, sirolimus-treated diabetic recipient mice, as opposed to mock-treated controls, were associated with dyslipidemia. These data suggest that sirolimus, administered in the early posttransplantation phase, is a confounding factor for reduced islet engraftment and impaired β-cell function in transplants.

[1]  R. Bottino,et al.  Therapeutic Angiogenesis for Islet Revascularization , 2006 .

[2]  D. Stolz,et al.  Harmful Delayed Effects of Exogenous Isolation Enzymes on Isolated Human Islets: Relevance to Clinical Transplantation , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  S. di Paolo,et al.  Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. , 2005, Journal of the American Society of Nephrology : JASN.

[4]  A. Shapiro,et al.  Five-year follow-up after clinical islet transplantation. , 2005, Diabetes.

[5]  J. Schrezenmeir,et al.  Effect of the immunosuppressive regime of Edmonton protocol on the long-term in vitro insulin secretion from islets of two different species and age categories. , 2005, Toxicology in vitro : an international journal published in association with BIBRA.

[6]  R. Nagai,et al.  Potent Inhibitory Effect of Sirolimus on Circulating Vascular Progenitor Cells , 2005, Circulation.

[7]  A. Shapiro,et al.  The Portal Immunosuppressive Storm: Relevance to Islet Transplantation? , 2005, Therapeutic drug monitoring.

[8]  A. Trapp,et al.  The Impact of Immunosuppression on Endothelial Function , 2005, Journal of cardiovascular pharmacology.

[9]  S. Schaffellner,et al.  Dyslipidemia during sirolimus therapy in patients after liver transplantation , 2004, Clinical transplantation.

[10]  J. Xu,et al.  Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. , 2004, The Journal of clinical investigation.

[11]  U. Gehling,et al.  Rapamycin inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. , 2004, Experimental cell research.

[12]  Marcela Brissova,et al.  Intraislet endothelial cells contribute to revascularization of transplanted pancreatic islets. , 2004, Diabetes.

[13]  N. Zhang,et al.  Elevated vascular endothelial growth factor production in islets improves islet graft vascularization. , 2004, Diabetes.

[14]  D. Melloul Transcription Factors in Islet Development and Physiology: Role of PDX‐1 in Beta‐Cell Function , 2004, Annals of the New York Academy of Sciences.

[15]  G. Mattsson,et al.  Evidence of functional impairment of syngeneically transplanted mouse pancreatic islets retrieved from the liver. , 2004, Diabetes.

[16]  G. Koehl,et al.  Rapamycin-Induced Endothelial Cell Death and Tumor Vessel Thrombosis Potentiate Cytotoxic Therapy against Pancreatic Cancer , 2004, Clinical Cancer Research.

[17]  A. F. Stewart,et al.  Hepatocyte growth factor gene therapy for pancreatic islets in diabetes: reducing the minimal islet transplant mass required in a glucocorticoid-free rat model of allogeneic portal vein islet transplantation. , 2004, Endocrinology.

[18]  Z. Bloomgarden,et al.  Angiogenic gene therapy for improving islet graft vascularization , 2004 .

[19]  A. Shapiro,et al.  Islet transplantation in patients with diabetes mellitus: choice of immunosuppression. , 2004, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.

[20]  B. Wolf,et al.  Elevated portal vein drug levels of sirolimus and tacrolimus in islet transplant recipients: local immunosuppression or islet toxicity? , 2003, Transplantation.

[21]  B. Wolf,et al.  Rapamycin has a deleterious effect on MIN-6 cells and rat and human islets. , 2003, Diabetes.

[22]  Jeffrey W Moses,et al.  Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.

[23]  S. Chueh,et al.  Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine–based immunosuppressive regimen: incidence, risk factors, progression, and prognosis1 , 2003, Transplantation.

[24]  H. Hammes,et al.  Angiogenic capacity of endothelial cells in islets of Langerhans , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[25]  R. Kirken,et al.  Molecular actions of sirolimus: sirolimus and mTor. , 2003, Transplantation proceedings.

[26]  B. Hering,et al.  Sirolimus and islet transplants. , 2003, Transplantation proceedings.

[27]  E. Schiff,et al.  A retrospective review of sirolimus (Rapamune) therapy in orthotopic liver transplant recipients diagnosed with chronic rejection , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[28]  G. Mattsson,et al.  Impaired revascularization of transplanted mouse pancreatic islets is chronic and glucose-independent1 , 2003, Transplantation.

[29]  J. Shapiro Eighty years after insulin: parallels with modern islet transplantation. , 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[30]  A. Shapiro,et al.  Successful islet transplantation: continued insulin reserve provides long-term glycemic control. , 2002, Diabetes.

[31]  P. Carlsson,et al.  Graft vascular function after transplantation of pancreatic islets , 2002, Diabetologia.

[32]  G. Mattsson,et al.  Decreased vascular density in mouse pancreatic islets after transplantation. , 2002, Diabetes.

[33]  G. Koehl,et al.  Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor , 2002, Nature Medicine.

[34]  M. Menger,et al.  Revascularization and Microcirculation of Freely Grafted Islets of Langerhans , 2001, World Journal of Surgery.

[35]  C. Ricordi,et al.  Human Islet Transplantation: Update , 2001, World Journal of Surgery.

[36]  P. Liss,et al.  Markedly decreased oxygen tension in transplanted rat pancreatic islets irrespective of the implantation site. , 2001, Diabetes.

[37]  R. Burcelin,et al.  Glucose sensing by the hepatoportal sensor is GLUT2-dependent: in vivo analysis in GLUT2-null mice. , 2000, Diabetes.

[38]  P. Liss,et al.  Chronically decreased oxygen tension in rat pancreatic islets transplanted under the kidney capsule. , 2000, Transplantation.

[39]  Ames,et al.  Islet Transplantation in Seven Patients with Type 1 Diabetes Mellitus Using a Glucocorticoid-Free Immunosuppressive Regimen , 2000 .

[40]  J. Li,et al.  Alpha-Gal oligosaccharides: chemistry and potential biomedical application. , 1999, Current medicinal chemistry.

[41]  M. Menger,et al.  Effects of cyclosporine A on the process of vascularization of freely transplanted islets of Langerhans , 1999, Journal of Molecular Medicine.

[42]  K. Messmer,et al.  Orientation of microvascular blood flow in pancreatic islet isografts. , 1994, The Journal of clinical investigation.

[43]  S. Lenzen,et al.  Regulation of glucokinase and GLUT-2 glucose-transporter gene expression in pancreatic B-cells. , 1991, The Biochemical journal.

[44]  K. Messmer,et al.  The influence of cyclosporine on the microvasculature of xenogeneic pancreatic islet grafts. , 1991, Transplantation proceedings.

[45]  C. Newgard,et al.  Glucokinase and glucose transporter expression in liver and islets: implications for control of glucose homoeostasis. , 1990, Biochemical Society transactions.

[46]  K. Messmer,et al.  The influence of prednisolone on revascularization of pancreatic islet grafts. , 1990, Transplantation proceedings.

[47]  A. Secchi,et al.  Islet-cell Transplantation , 1975, The Lancet.